Cencora, Inc. COR
Composite 52/100; the shares have moved about 36% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Income ranks 43/100 — a slight mark against it.
Growth ranks 56/100 — a slight point in its favour. Quality ranks 55/100 — a slight point in its favour. Momentum ranks 54/100 — a slight point in its favour.
Income ranks 43/100 — a slight mark against it. Balance-sheet strength ranks 47/100 — a slight mark against it.
What the company does Cencora, Inc. (COR) distributes pharmaceutical products, including generics, injectables, vaccines, and specialty drugs, to hospitals, pharmacies, and animal-health markets. It also provides pharmacy management, data analytics, and clinical trial support services to biopharma clients.
Key financials COR’s profitability metrics are strong: ROE 96.9%, ROA 3.6%, and ROCE 16.6%. Margins are modest: gross 4.0%, operating 1.4%, net 0.8%. Revenue and EPS growth are 9.3% and 5.9%, respectively. Debt is high (Debt/Equity 4.47), but coverage (8.20x) and liquidity (Current ratio 0.94) are manageable.
Stock health Momentum is mixed: +18.00% over 3 months, -11.17% over 6 months, and +7.59% over 12 months. The stock is -13.74% below its 52-week high, with RSI(14) at 59.30. Sideravia scores are average: Quality 55.9, Growth 58.6, Strength 47.8, Valuation 47.4, Momentum 46.9, Income 40.9.
Price vs fair value The stock trades at a **discount** of 14.10% versus the analyst mean target of 369.31. - COR’s premium valuation (P/E 23.54, EV/EBITDA 13.38) contrasts with peers like McKesson’s accelerating oncology/GLP-1 growth (Zacks). - Analysts question McKesson’s valuation amid growth, highlighting sector-wide premiums (Zacks).
Looking forward Forward P/E (15.87) and PEG (0.33) suggest undemanding multiples relative to growth. However, high leverage and modest net margins may limit multiple expansion. Analysts’ 369.31 target implies 14.10% upside from the current price.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.